Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZXH
|
|||
| Former ID |
DIB016192
|
|||
| Drug Name |
PHN-131
|
|||
| Synonyms |
NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2/3 | [1] | |
| Company |
PhytoHealth Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H28ClNO4
|
|||
| Canonical SMILES |
C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O.Cl
|
|||
| InChI |
1S/C21H27NO4.ClH/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12;/h4-5,12,15-16,19,23-25H,1-3,6-11H2;1H/t15-,16+,19-,20-,21+;/m0./s1
|
|||
| InChIKey |
YZLZPSJXMWGIFH-BCXQGASESA-N
|
|||
| CAS Number |
CAS 23277-43-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:7455
|
|||
| ADReCS Drug ID | BADD_D01520 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029095) | |||
| REF 2 | Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.